BioArctic AB (publ) (ST:BIOA-B) — Market Cap & Net Worth
Market Cap & Net Worth: BioArctic AB (publ) (BIOA-B)
BioArctic AB (publ) (ST:BIOA-B) has a market capitalization of $2.29 Billion (Skr21.23 Billion) as of June 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #5896 globally and #80 in its home market, demonstrating a -2.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioArctic AB (publ)'s stock price Skr286.00 by its total outstanding shares 74241489 (74.24 Million). Review BioArctic AB (publ) debt and liabilities to assess the company's total debt and financial obligations.
BioArctic AB (publ) Market Cap History: 2017 to 2026
BioArctic AB (publ)'s market capitalization history from 2017 to 2026. Data shows growth from $203.60 Million to $2.29 Billion (30.46% CAGR).
BioArctic AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioArctic AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.19x
BioArctic AB (publ)'s market cap is 6.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $203.60 Million | $140.71 Million | $15.16 Million | 1.45x | 13.43x |
| 2018 | $642.13 Million | $713.97 Million | $381.60 Million | 0.90x | 1.68x |
| 2019 | $758.21 Million | $281.77 Million | $88.47 Million | 2.69x | 8.57x |
| 2020 | $762.20 Million | $62.35 Million | -$68.52 Million | 12.23x | N/A |
| 2021 | $952.36 Million | $23.15 Million | -$119.79 Million | 41.15x | N/A |
| 2022 | $2.17 Billion | $228.29 Million | -$11.18 Million | 9.52x | N/A |
| 2023 | $2.14 Billion | $616.00 Million | $229.25 Million | 3.47x | 9.33x |
| 2024 | $1.59 Billion | $257.35 Million | -$177.08 Million | 6.19x | N/A |
Competitor Companies of BIOA-B by Market Capitalization
Companies near BioArctic AB (publ) in the global market cap rankings as of June 17, 2026.
Key companies related to BioArctic AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
BioArctic AB (publ) Historical Marketcap From 2017 to 2026
Between 2017 and today, BioArctic AB (publ)'s market cap moved from $203.60 Million to $ 2.29 Billion, with a yearly change of 30.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr2.29 Billion | -7.98% |
| 2025 | Skr2.48 Billion | +55.79% |
| 2024 | Skr1.59 Billion | -25.50% |
| 2023 | Skr2.14 Billion | -1.54% |
| 2022 | Skr2.17 Billion | +128.19% |
| 2021 | Skr952.36 Million | +24.95% |
| 2020 | Skr762.20 Million | +0.53% |
| 2019 | Skr758.21 Million | +18.08% |
| 2018 | Skr642.13 Million | +215.39% |
| 2017 | Skr203.60 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of BioArctic AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.29 Billion USD |
| MoneyControl | $2.29 Billion USD |
| MarketWatch | $2.29 Billion USD |
| marketcap.company | $2.29 Billion USD |
| Reuters | $2.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more